1-9 of 9
David M. Jackman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6010–6020.
https://doi.org/10.1158/1078-0432.CCR-16-0909
Published: 15 December 2016
View article titled, A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <em>EGFR</em>-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Open the PDF for A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <em>EGFR</em>-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2851–2860.
https://doi.org/10.1158/1078-0432.CCR-14-3112
Published: 14 June 2015
View article titled, Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <em>KRAS</em>-Mutant Lung Adenocarcinoma
Open the PDF for Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <em>KRAS</em>-Mutant Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Stacy L. Mach, Allison O'Connell, Melissa M. Messineo, Jason J. Luke, Mohit Butaney, Paul Kirschmeier, David M. Jackman, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1698–1705.
https://doi.org/10.1158/1078-0432.CCR-13-2482
Published: 13 March 2014
View article titled, Noninvasive Detection of Response and Resistance in <em>EGFR</em>-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Open the PDF for Noninvasive Detection of Response and Resistance in <em>EGFR</em>-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA in another window
Includes: Supplementary data
Journal Articles

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

Stephanie Heon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4406–4414.
https://doi.org/10.1158/1078-0432.CCR-12-0357
Published: 14 August 2012
View article titled, The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <em>EGFR</em> Mutations
Open the PDF for The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <em>EGFR</em> Mutations in another window
Journal Articles

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (23): 5873–5882.
https://doi.org/10.1158/1078-0432.CCR-10-1588
Published: 06 December 2010
View article titled, Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <em>EGFR</em> Mutations Treated with Gefitinib or Erlotinib
Open the PDF for Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <em>EGFR</em> Mutations Treated with Gefitinib or Erlotinib in another window
Journal Articles

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

David M. Jackman, Vincent A. Miller, Leigh-Anne Cioffredi, Beow Y. Yeap, Pasi A. Jänne, Gregory J. Riely, Marielle Gallegos Ruiz, Giuseppe Giaccone, Lecia V. Sequist, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5267–5273.
https://doi.org/10.1158/1078-0432.CCR-09-0888
Published: 12 August 2009
View article titled, Impact of Epidermal Growth Factor Receptor and <em>KRAS</em> Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Open the PDF for Impact of Epidermal Growth Factor Receptor and <em>KRAS</em> Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials in another window
Journal Articles

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Kimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, Alison J. Homes, David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6963–6973.
https://doi.org/10.1158/1078-0432.CCR-08-0957
Published: 03 November 2008
View article titled, Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <em>EGFR</em> Wild-type Cancers
Open the PDF for Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <em>EGFR</em> Wild-type Cancers in another window
Includes: Supplementary data
Journal Articles

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Daniel B. Costa, Kim-Son H. Nguyen, Byoung C. Cho, Lecia V. Sequist, David M. Jackman, Gregory J. Riely, Beow Y. Yeap, Balázs Halmos, Joo H. Kim, Pasi A. Jänne, Mark S. Huberman, William Pao, Daniel G. Tenen, Susumu Kobayashi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7060–7067.
https://doi.org/10.1158/1078-0432.CCR-08-1455
Published: 03 November 2008
View article titled, Effects of Erlotinib in <em>EGFR</em> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
Open the PDF for Effects of Erlotinib in <em>EGFR</em> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib in another window
Journal Articles

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balazs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3908–3914.
https://doi.org/10.1158/1078-0432.CCR-06-0462
Published: 03 July 2006
View article titled, Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Open the PDF for Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib in another window